ERBB2 and breast carcinoma: Based on the very favorable results of recent clinical trials, the anti-HER2 ADC trastuzumab deruxtecan has been approved for the treatment of metastatic HER2-low breast cancer, which emphasizes the importance of defining HER2-low tumors and promotes the investigation of biologic roles of HER2-low expression in breast cancer [3, 5].